Opportunities and challenges in combining immunotherapy and radiotherapy in head and neck cancers

Cancer Treat Rev. 2022 Apr;105:102361. doi: 10.1016/j.ctrv.2022.102361. Epub 2022 Feb 16.

Abstract

Locally advanced and recurrent/ metastatic (R/M) head and neck cancers have poor prognosis generally. Radiotherapy (RT) is known to have multiple immunomodulatory effects, and various immune checkpoint inhibitors (ICIs) have been shown to be efficacious in the R/M setting in recent years. Hence, it is logical to combine RT and ICIs to improve the outlook for such patients, especially in view of the promising pre-clinical data on this novel combination. In this review, we highlighted the key mechanisms underlying the immunostimulatory and immunoinhibitory effects of RT, with a view to suggesting strategies to overcome radioresistance. We also discussed how the unique immune landscapes of virus-induced cancers, namely Epstein-Barr virus-induced nasopharyngeal carcinoma and human papillomavirus-mediated oropharyngeal cancer, could be exploited with ICIs. The landmark clinical trials in both the locally advanced and R/M settings were reviewed, and these trials showed that the combination of RT and ICIs is generally well tolerated. The potential reasons behind the largely negative results of these studies were also explored, focusing on various parameters including dose fractionation, sequencing, irradiated volume and the use of predictive biomarkers.

Keywords: Head and neck neoplasms; Immunotherapy; Nasopharyngeal carcinoma; Oropharyngeal neoplasms; Radiotherapy.

Publication types

  • Review

MeSH terms

  • Epstein-Barr Virus Infections* / complications
  • Head and Neck Neoplasms* / drug therapy
  • Head and Neck Neoplasms* / radiotherapy
  • Herpesvirus 4, Human
  • Humans
  • Immunotherapy / methods
  • Nasopharyngeal Neoplasms*
  • Neoplasm Recurrence, Local / drug therapy
  • Squamous Cell Carcinoma of Head and Neck